ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Archives for February 2017

Gerard A. Silvestri, MD, MS, FCCP

on: February 01, 2017In: Names & News
Gerard A. Silvestri, MD, MS, FCCP

Posted: February 2017 Gerard A. Silvestri is the 79th President of the American College of Chest Physicians, effective November 2017. Dr. Silvestri is Hillenbrand Professor of Thoracic Oncology and Vice-Chair of […] Read more


John C. Ruckdeschel, MD

on: February 01, 2017In: Names & News
John C. Ruckdeschel, MD

Posted: February 2017 John C. Ruckdeschel has been appointed Director, University of Mississippi Medical Center Cancer Institute, Jackson, MS. Previous to this appointment, Dr. Ruckdeschel was Medical Director, Oncology Program and […] Read more

Ugo Pastorino, MD

on: February 01, 2017In: Names & News
Ugo Pastorino, MD

Posted: February 2017 Ugo Pastorino received the Joseph W. Cullen/Early Detection Award, which is given to to a lung cancer specialist in recognition of his or her scientific achievements in research […] Read more

Keunchil Park, MD, PhD

on: February 01, 2017In: Names & News
Keunchil Park, MD, PhD

Posted: February 2017 Keunchil Park received the 2016 IASLC Merit Award, which is given to lung cancer specialists who have made extraordinary contributions to the IASLC’s development. Dr. Park is Professor, […] Read more

Dr. Benjamin Levy, MD

on: February 01, 2017In: Names & News
Dr. Benjamin Levy, MD

Posted: February 2017 Dr. Benjamin Levy has been appointed Clinical Director, Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital and Medical Director of the Thoracic Oncology Program in Washington, […] Read more

Keith Kerr, BSc, MB ChB, FRCPath, FRCPE

on: February 01, 2017In: Names & News
Keith Kerr, BSc, MB ChB, FRCPath, FRCPE

Posted: February 2017 Keith Kerr received the 2016 IASLC Mary J. Matthews Pathology/ Translational Research Award, which is given to a scientist for lifetime scientific achievements in pathology/translational research of thoracic […] Read more

Roy S. Herbst, MD, PhD

on: February 01, 2017In: Names & News
Roy S. Herbst, MD, PhD

Posted: February 2017 Roy S. Herbst received the 2016 IASLC Paul A. Bunn, Jr. Scientific Award, which is given to an oncologist who has made outstanding scientific contributions to thoracic cancer […] Read more

Peter Hammerman, MD, PhD

on: February 01, 2017In: Names & News
Peter Hammerman, MD, PhD

Posted: February 2017 Peter Hammerman has been appointed Global Head, Oncology Translational Research at Novartis Institutes for BioMedical Research (NIBR). Previous to this appointment, Dr. Hammerman was a Medical Oncologist and […] Read more

FDA Corner – Interview with Amy Mckee, MD

on: February 01, 2017In: Regulatory Agency Perspective
FDA Corner - Interview with Amy Mckee, MD

Posted: February 2017 BY Erik J. Maclaren, PhD Breakthrough Therapy Designation and Mechanisms of Expedited Review The U.S. Food and Drug Administration (FDA) is responsible for reviewing the evidence of […] Read more

PD-L1 Blueprint Project

on: February 01, 2017In: Systemic, Targeted, & Immune Therapies
PD-L1 Blueprint Project

Posted: February 2017 By Fred R. Hirsch, MD, PhD In the new era of immunotherapy in thoracic cancer, evaluating PD-L1 status remains a clinical challenge. In recognition of the potential […] Read more

123

SEARCH ILCN

Archives

PROVIDER RESOURCES

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED


MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy